BCL2 and prostate carcinoma: The BCL2 apoptosis regulator [P10415], also validated only in one study that includes 22 patients from Qatar [52], is the target for 14 drugs, with ten of them used for cancer treatment and only two of them for prostate cancer (Table 1).